WebSep 15, 2024 · Cisplatin is mutagenic, teratogenic and carcinogenic and its use has been show to increase the risk of secondary malignancies, particularly leukemia. … WebChemotherapy agents that have an increased risk for second cancers include: Alkylating agents (mechlorethamine, chlorambucil, cyclophosphamide, melphalan, lomustine, …
Cisplatin Cancer information Cancer Research UK
WebApr 11, 2024 · Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS; and LiPlaCis ® , a liposomal formulation of … WebJun 1, 2024 · tion with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol 2015;16:967-978. DOI: 10.1016/S1470-2045(15)00139-4 . 3. Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, grabr investment
Cisplatin/gemcitabine/pirarubicin SpringerLink
WebPlatinum chemotherapy, particularly cisplatin, is commonly associated with electrolyte imbalances, including hypomagnesemia, hypokalemia, hypophosphatemia, hypocalcemia and hyponatremia. The corpus of literature on these dyselectrolytemias is large; the objective of this review is to synthesize the … WebFeb 1, 2013 · What are secondary malignancies? A secondary malignancy is a new cancer that occurs in an individual as a result of previous treatment with radiation or … WebTreatment of lung cancer, the most common type of carcinoma, is difficult due to disease progression at the time of diagnosis, causing a high mortality rate. 1, 32 Cisplatin (DDP), also known as cis-diaminodichloplatin, is a powerful nonspecific drug blocking the cell cycle. 33, 34 DDP can enter cells through the passive transport. grab reward spotify